PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
-3.88%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$1.31B
AUM Growth
+$1.31B
(-25%)
Cap. Flow
-$296M
Cap. Flow
% of AUM
-22.54%
Top 10 Holdings %
Top 10 Hldgs %
50.96%
Holding
96
New
18
Increased
9
Reduced
25
Closed
19
Top Buys
| 1 |
DexCom
DXCM
|
$25.6M |
| 2 |
Neurocrine Biosciences
NBIX
|
$22.8M |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
$21.7M |
| 4 |
Invesco S&P 500 Equal Weight ETF
RSP
|
$18.9M |
| 5 |
United Therapeutics
UTHR
|
$18.5M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$92.8M |
| 2 |
Merck
MRK
|
$61.6M |
| 3 |
Acadia Healthcare
ACHC
|
$43.5M |
| 4 |
Elevance Health
ELV
|
$29.3M |
| 5 |
Amgen
AMGN
|
$29.1M |
Sector Composition
| 1 | Healthcare | 92.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Metagenomi
MGX
$67.2M
| $3.2M | 0.2% |
885,803
-148,199
| -14% | -$535K |
|
52
PMV Pharmaceuticals
PMVP
$82.1M
| $3.14M | 0.19% |
2,079,245
+68,205
| +3% | +$103K |
|
53
Insmed
INSM
$30.3B
| $3.02M | 0.19% |
43,774
-108,454
| -71% | -$7.49M |
|
54
TG Therapeutics
TGTX
$5.03B
| $2.97M | 0.18% |
98,674
-134,736
| -58% | -$4.06M |
|
55
Sagimet Biosciences
SGMT
$239M
| $2.92M | 0.18% |
649,006
| – | – |
|
56
Syndax Pharmaceuticals
SNDX
$1.39B
| $2.73M | 0.17% |
206,871
-217,039
| -51% | -$2.87M |
|
|
ADAP
57
Adaptimmune Therapeutics
ADAP
$13.9M
| $2.62M | 0.16% |
4,871,969
-5,128,818
| -51% | -$2.76M |
|
58
Alkermes
ALKS
$4.95B
| $2.32M | 0.14% |
80,719
-124,354
| -61% | -$3.58M |
|
59
Jazz Pharmaceuticals
JAZZ
$7.99B
| $2.17M | 0.13% |
+17,597
| New | +$2.17M |
|
60
IO Biotech
IOBT
$115M
| $2.15M | 0.13% |
2,341,107
| – | – |
|
61
Inhibrx
INBX
$403M
| $2.09M | 0.13% |
135,546
| – | – |
|
62
Celcuity
CELC
$2.3B
| $2.08M | 0.13% |
158,746
-551,509
| -78% | -$7.22M |
|
|
CMPS
63
Compass Pathways
CMPS
$452M
| $1.71M | 0.11% |
451,267
| – | – |
|
64
Keros Therapeutics
KROS
$640M
| $1.65M | 0.1% |
104,323
+3,273
| +3% | +$51.8K |
|
65
Iovance Biotherapeutics
IOVA
$800M
| $978K | 0.06% |
132,152
| – | – |
|
66
Generation Bio
GBIO
$40.3M
| $835K | 0.05% |
787,914
| – | – |
|
67
Capricor Therapeutics
CAPR
$287M
| $750K | 0.05% |
54,357
-98,422
| -64% | -$1.36M |
|
|
VERV
68
DELISTED
Verve Therapeutics
VERV
| $711K | 0.04% |
125,999
| – | – |
|
|
BOLD
69
Boundless Bio
BOLD
$25.7M
| $697K | 0.04% |
240,513
| – | – |
|
|
BLUE
70
DELISTED
bluebird bio
BLUE
| $632K | 0.04% |
+75,758
| New | +$632K |
|
|
TSBX
71
DELISTED
Turnstone Biologics
TSBX
| $463K | 0.03% |
932,348
| – | – |
|
|
LBPH
72
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – |
-113,711
| Closed | -$3.79M |
|
|
CON
73
Concentra Group Holdings Parent, Inc.
CON
$3.04B
| – | – |
-300,000
| Closed | -$6.71M |
|
74
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
-121,845
| Closed | -$12M |
|
|
SWTX
75
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
0
| – | – |
|